Bohuslav Melichar1, Jaroslav Cerman, Eva Malírová. 1. Department of Medicine, Charles University Medical School and Teaching Hospital, Sokolská 581, 500 05, Hradec Králové, Czech Republic. melichar@fnhk.cz
Abstract
INTRODUCTION: Cetuximab is a chimeric antibody registered for the therapy of advanced colorectal carcinoma after failure of standard chemotherapy. Rare infusion reactions that resulted in the cessation of therapy have been described after cetuximab administration. CASE DESCRIPTION: We have observed severe infusion reactions accompanied by a loss of consciousness in two patients. The patients were transferred to intensive care unit, and the treatment was continued after administration of corticosteroids under careful monitoring of vital signs without any further serious reactions. In both cases, benefit of therapy with cetuximab could be demonstrated. CONCLUSION: This experience indicates that cetuximab can be continued in patients who experience infusion reactions. Surveillance in the intensive care unit is mandatory during readministration of the drug.
INTRODUCTION:Cetuximab is a chimeric antibody registered for the therapy of advanced colorectal carcinoma after failure of standard chemotherapy. Rare infusion reactions that resulted in the cessation of therapy have been described after cetuximab administration. CASE DESCRIPTION: We have observed severe infusion reactions accompanied by a loss of consciousness in two patients. The patients were transferred to intensive care unit, and the treatment was continued after administration of corticosteroids under careful monitoring of vital signs without any further serious reactions. In both cases, benefit of therapy with cetuximab could be demonstrated. CONCLUSION: This experience indicates that cetuximab can be continued in patients who experience infusion reactions. Surveillance in the intensive care unit is mandatory during readministration of the drug.
Authors: D M Shin; N J Donato; R Perez-Soler; H J Shin; J Y Wu; P Zhang; K Lawhorn; F R Khuri; B S Glisson; J Myers; G Clayman; D Pfister; J Falcey; H Waksal; J Mendelsohn; W K Hong Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: J C Byrd; J K Waselenko; T J Maneatis; T Murphy; F T Ward; B P Monahan; M A Sipe; S Donegan; C A White Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem Journal: N Engl J Med Date: 2004-07-22 Impact factor: 91.245
Authors: Leonard B Saltz; Neal J Meropol; Patrick J Loehrer; Michael N Needle; Justin Kopit; Robert J Mayer Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245
Authors: Andreas Dietz; Andreas Boehm; Christian Mozet; Gunnar Wichmann; Athanassios Giannis Journal: Eur Arch Otorhinolaryngol Date: 2008-07 Impact factor: 2.503